Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arcturus Therapeutics Ltd (ARCT)

Arcturus Therapeutics Ltd (ARCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,436,137
  • Shares Outstanding, K 26,327
  • Annual Sales, $ 9,540 K
  • Annual Income, $ -72,150 K
  • 60-Month Beta 2.91
  • Price/Sales 145.12
  • Price/Cash Flow N/A
  • Price/Book 4.05
Trade ARCT with:

Options Overview Details

View History
  • Implied Volatility 87.63%
  • Historical Volatility 59.07%
  • IV Percentile 12%
  • IV Rank 18.97%
  • IV High 147.80% on 08/03/21
  • IV Low 73.54% on 06/17/21
  • Put/Call Vol Ratio 0.40
  • Today's Volume 372
  • Volume Avg (30-Day) 787
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 4,709
  • Open Int (30-Day) 9,309

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -1.37
  • Number of Estimates 6
  • High Estimate 0.30
  • Low Estimate -2.59
  • Prior Year -0.92
  • Growth Rate Est. (year over year) -48.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.80 +1.83%
on 09/20/21
58.45 -13.24%
on 09/02/21
-0.53 (-1.03%)
since 08/24/21
3-Month
26.92 +88.37%
on 07/15/21
65.00 -21.98%
on 08/10/21
+16.39 (+47.76%)
since 06/24/21
52-Week
24.87 +103.90%
on 05/13/21
129.71 -60.91%
on 12/07/20
+13.22 (+35.26%)
since 09/24/20

Most Recent Stories

More News
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant...

ARCT : 50.71 (-7.04%)
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR(TM) mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

--Phase 2 (300 participants) has initiated

ARCT : 50.71 (-7.04%)
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant...

ARCT : 50.71 (-7.04%)
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant...

ARCT : 50.71 (-7.04%)
June 2022 Options Now Available For Arcturus Therapeutics Holdings (ARCT)

Investors in Arcturus Therapeutics Holdings Inc saw new options become available today, for the June 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay,...

ARCT : 50.71 (-7.04%)
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -4.02% and -27.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ARCT : 50.71 (-7.04%)
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

--ARCT-154, Arcturus' STARR(TM) mRNA vaccine candidate targeting COVID variants of concern, elicits robust neutralizing antibody titers against all variants tested in primates, including the Delta variant...

ARCT : 50.71 (-7.04%)
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR(TM) mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study

--ARCT-154 and ARCT-165 elicit high levels of neutralizing antibodies in non-human primates against multiple variants of concern

ARCT : 50.71 (-7.04%)
Earnings Preview: Arcturus Therapeutics (ARCT) Q2 Earnings Expected to Decline

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARCT : 50.71 (-7.04%)
Vingroup collaborates with Arcturus Therapeutics to establish a manufacturing facility in Vietnam for Arcturus’ mRNA Covid-19 vaccine

--News Direct--

TKPYY : 16.5900 (-0.90%)
ARCT : 50.71 (-7.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as...

See More

Key Turning Points

3rd Resistance Point 55.95
2nd Resistance Point 54.81
1st Resistance Point 52.76
Last Price 50.71
1st Support Level 49.57
2nd Support Level 48.44
3rd Support Level 46.39

See More

52-Week High 129.71
Fibonacci 61.8% 89.66
Fibonacci 50% 77.29
Fibonacci 38.2% 64.92
Last Price 50.71
52-Week Low 24.87

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar